<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983944</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08178</org_study_id>
    <secondary_id>NCI-2011-03123</secondary_id>
    <nct_id>NCT00983944</nct_id>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma</brief_title>
  <official_title>A Randomized Phase II Study of Dose-Adjusted EPOCH-R and R-VACOP-B in Primary Mediastinal (Thymic) Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving rituximab together with combination chemotherapy may kill more&#xD;
      cancer cells. It is not yet known which combination chemotherapy regimen is more effective&#xD;
      when given with rituximab in treating large B-cell lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well rituximab and combination&#xD;
      chemotherapy work when given with or without bleomycin sulfate in treating patients with&#xD;
      primary mediastinal large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the complete response rate based on PET/CT scan criteria in patients with&#xD;
           primary mediastinal large B-cell lymphoma (PMLCL) treated with dose-adjusted rituximab,&#xD;
           etoposide, doxorubicin hydrochloride, vincristine sulfate, cyclophosphamide, and&#xD;
           prednisone with or without bleomycin sulfate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the progression-free survival (PFS) of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To assess the toxicity profiles associated with these regimens in these patients.&#xD;
&#xD;
        -  To determine the prognostic significance of a mid-therapy PET scan and an end-of-therapy&#xD;
           PET scan in achieving complete response and in predicting 2-year PFS of patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  To explore the effect of involved-field radiotherapy on 2-year PFS of patients who are&#xD;
           PET positive at the end of chemotherapy.&#xD;
&#xD;
        -  To explore the efficacy of an end-of-therapy PET/CT scan in predicting which patients&#xD;
           can avoid radiotherapy.&#xD;
&#xD;
        -  To characterize the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  To prospectively validate a pattern of immunohistochemical staining, including nuclear&#xD;
           c-REL, TRAF-1, c-JUN, and Gal1, to accurately distinguish PMLCL from other lymphoid&#xD;
           malignancies.&#xD;
&#xD;
        -  To determine if levels of soluble CD30 correlate with disease activity in PMLCL.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (EPOCH-R): Patients receive rituximab IV on day 1; etoposide IV, doxorubicin&#xD;
           hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4;&#xD;
           cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days&#xD;
           1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (R-VACOP-B): Patients receive rituximab IV and doxorubicin hydrochloride IV on&#xD;
           day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of&#xD;
           weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of&#xD;
           weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2,&#xD;
           4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day&#xD;
           in weeks 2-10.&#xD;
&#xD;
      In both arms, patients undergo PET/CT scans at baseline, mid-therapy, and after completion of&#xD;
      chemotherapy. Patients with stable or progressive disease after completion of chemotherapy&#xD;
      are removed from the study. Patients with complete response undergo observation. Patients&#xD;
      with partial response undergo involved-field radiotherapy to any area of bulky disease at&#xD;
      diagnosis and to any FDG-avid area on PET scan 3-4 weeks after completion of chemotherapy.&#xD;
      These patients then undergo additional PET/CT scan at 8-10 weeks after completion of&#xD;
      radiotherapy.&#xD;
&#xD;
      Blood samples are collected at baseline, during mid-therapy restaging, and after completion&#xD;
      of chemotherapy for analysis of soluble CD30 levels by ELISA. Previously collected tissue&#xD;
      samples are obtained for biomarker analysis by IHC.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Inadequate Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">April 25, 2011</completion_date>
  <primary_completion_date type="Actual">April 25, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to a year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two-year progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical staining results</measure>
    <time_frame>Up to a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of soluble CD30 levels with disease activity in PMLCL</measure>
    <time_frame>Up to a year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPOCH regimen</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I (EPOCH-R)</arm_group_label>
    <arm_group_label>Arm II (R-VACOP-B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary mediastinal (thymic) large B-cell lymphoma as defined&#xD;
             by WHO classification of lymphoid neoplasms&#xD;
&#xD;
               -  Diagnosis must be based on an adequate tissue sample, such as an excisional&#xD;
                  biopsy or core-needle biopsy&#xD;
&#xD;
          -  A paraffin-embedded block of well-fixed lymphoma tissue must be available&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
             dimension as ≥ 10 mm&#xD;
&#xD;
          -  No active or untreated CNS lymphoma&#xD;
&#xD;
               -  A lumbar puncture is not required in the absence of neurologic symptoms&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/mm^3 (unless related to disease)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (unless related to disease)&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and/or ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Ejection fraction ≥ 45% by MUGA or echocardiogram&#xD;
&#xD;
          -  Patients with HIV infection are eligible, provided the following criteria are met:&#xD;
&#xD;
               -  No evidence of co-infection with hepatitis B or C&#xD;
&#xD;
               -  CD4 cell count ≥ 400/mm^3&#xD;
&#xD;
               -  No evidence of resistant strains of HIV&#xD;
&#xD;
               -  HIV viral load ≤ 10,000 copies HIV RNA/mL (if not on anti-HIV therapy)&#xD;
&#xD;
               -  HIV viral load ≤ 50 copies HIV RNA/mL (if on anti-HIV therapy)&#xD;
&#xD;
               -  No history of AIDS-defining conditions&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No active secondary malignancy except nonmelanomatous skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy or rituximab&#xD;
&#xD;
               -  Prior limited course of glucocorticoids allowed&#xD;
&#xD;
          -  No other concurrent investigational or commercial anticancer therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristie A. Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

